Protection against fetal infection with either bovine viral diarrhea virus type 1 or type 2 using a noncytopathic type 1 modified-live virus vaccine.

Two bovine viral diarrhea virus (BVDV) fetal protection studies were done using a monovalent noncytopathic (NCP) BVDV vaccine containing type 1 BVDV. In study 1, thirty-two fetuses (23 vaccinates and nine controls) were recovered following fetal challenge with the type 1a BJ strain. Twenty of 23 fetuses from the vaccinates were negative for BVDV type 1, but all of the controls (nine of nine) were infected. In study 2, 22 animals (14 vaccinates and eight controls) were challenged with the type 2 PA131 strain. Thirteen of the 14 fetuses from the vaccinates were negative for BVDV type 2, but all of the nonvaccinated controls (eight of eight) were infected. These results indicate the efficacy of a monovalent NCP BVDV vaccine in providing excellent protection against either BVDV type 1 or type 2 fetal infection. Protection against Fetal Infection with Either Bovine Viral Diarrhea Virus Type 1 or Type 2 Using a Noncytopathic Type 1 Modified-Live Virus Vaccine*